moderna adverse reaction reporting phone number

Moderna adverse reaction reporting phone number series#

The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis ( ). The observed risk is highest in males 18 years through 24 years of age. Myocarditis and Pericarditis: Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination. Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines ( ). Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the vaccine. ‡‡ For immunocompromised individuals 5 years through 11 years of age, the last dose of a COVID-19 vaccine (2023-2024 formula) refers to a dose with Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) or Moderna COVID-19 Vaccine (2023-2024 Formula).ĭo not administer the vaccine to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent. †† For immunocompromised individuals 6 months through 4 years of age, the last dose of a COVID-19 vaccine (2023-2024 formula) refers to a dose with Moderna COVID-19 Vaccine (2023-2024 Formula). ** For immunocompromised individuals 5 years through 11 years of age, the last previous dose refers to the last dose of a COVID-19 vaccine (original monovalent) or bivalent COVID-19 vaccine which are no longer authorized for use in the U.S. # For immunocompromised individuals 6 months through 4 years of age, the last previous dose refers to the last dose of Moderna COVID-19 Vaccine (Original monovalent) or Moderna COVID-19 Vaccine, Bivalent which are no longer authorized for use in the U.S.

Moderna adverse reaction reporting phone number series#

Individuals turning from 11 to 12 years of age during the vaccination series may complete the series with doses of Moderna COVID-19 Vaccine (2023-2024 Formula). ¶ COVID-19 vaccine, each dose of the 3-doses series given one month apart, refers to Moderna COVID-19 vaccines. || COVID-19 vaccine refers to the monovalent COVID-19 vaccines that encode the spike protein of the original SARS-CoV-2 and the bivalent COVID-19 vaccines encoding the spike protein of original SARS-CoV-2 and of the Omicron variant lineages BA.4 and BA.5 that are no longer authorized for use in the United States. § Individuals turning from 4 years to 5 years of age during the vaccination series should receive both doses with Moderna COVID-19 Vaccine (2023-2024 Formula). “Certain kinds of immunocompromise” refers to individuals who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

At least 1 dose should be with a COVID-19 vaccine (2023-2024 formula). ‡ Individuals with certain kinds of immunocompromise 6 months through 11 years of age should complete at least a 3-dose series with a COVID-19 vaccine, each dose 1 month apart. † Not previously vaccinated with any COVID-19 vaccine. These vaccines are no longer authorized for use in the United States. * Previous dose(s) of Moderna COVID-19 vaccine(s) refers to Moderna COVID-19 Vaccine (Original monovalent) and Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5). The timing of the additional doses may be based on the individual’s clinical circumstances. ††‡‡ Additional doses of Moderna COVID-19 Vaccine (2023-2024 Formula) may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances. #**Īn additional dose of Moderna COVID-19 Vaccine (2023-2024 Formula) may be administered at least 2 months following the last dose of a COVID-19 vaccine (2023-2024 formula). If previously vaccinated with three or more doses, administer a single dose of Moderna COVID-19 Vaccine (2023-2024 Formula) at least two months following the last previous dose. If previously vaccinated with one or two dose(s) of Moderna COVID-19 Vaccine (Original monovalent) and/or the Moderna COVID-19 Vaccine, Bivalent, complete the remaining dose(s) in the three-dose series with Moderna COVID-19 Vaccine (2023-2024 Formula). If previously not vaccinated, complete the three-dose series with Moderna COVID-19 Vaccine (2023-2024 Formula).

¶ At least 1 dose should be with a COVID-19 vaccine (2023-2024 formula). Individuals 6 months through 11 years of age with certain kinds of immunocompromise ‡ should complete at least a three-dose series with a COVID-19 vaccine, each dose one month apart. Dosing Updates for Individuals With Certain Kinds of Immunocompromise